Active, not recruitingPHASE1, PHASE2NCT04120493

Safety and Proof-of-Concept (POC) Study With AMT-130 in Adults With Early Manifest Huntington's Disease

Studying Huntington's Disease

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
UniQure Biopharma B.V.
Principal Investigator
David H. Margolin, MD, PhD
uniQure, Inc.
Intervention
intra-striatal rAAV5-miHTT(genetic)
Enrollment
43 enrolled
Eligibility
25-65 years · All sexes
Timeline
20192029

Study locations (12)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04120493 on ClinicalTrials.gov

Other trials for Huntington's Disease

Additional recruiting or active studies for the same condition.

See all trials for Huntington's Disease

← Back to all trials